Response to bortezomib and activation of osteoblasts in multiple myeloma
M Zangari, S Yaccoby, F Cavallo, D Esseltine… - Clinical Lymphoma and …, 2006 - Elsevier
Histomorphometry and biochemical markers of bone turnover have shown that, although
osteoclast activity is increased in multiple myeloma (MM), mostly through the receptor
activator of nuclear factor–κB ligand/osteoprotegerin axis, the key element in vivo to
determine the presence or absence of osteolytic lesions resides on the presence and activity
of osteoblasts. The loss of bone observed in MM is the result of an uncoupling of bone
formation and bone resorption. Bortezomib is a first-in-class proteasome inhibitor developed …
osteoclast activity is increased in multiple myeloma (MM), mostly through the receptor
activator of nuclear factor–κB ligand/osteoprotegerin axis, the key element in vivo to
determine the presence or absence of osteolytic lesions resides on the presence and activity
of osteoblasts. The loss of bone observed in MM is the result of an uncoupling of bone
formation and bone resorption. Bortezomib is a first-in-class proteasome inhibitor developed …